

I. AMENDMENTS

AMENDMENTS TO THE CLAIMS

Cancel claims 1-25 without prejudice to renewal.

Please enter new claims 27-36, as shown below.

1.-25. (Canceled)

26. (Currently amended) A method of treating nasal polyps, comprising administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist to a patient suffering from nasal polyps.

27. (New) The method of claim 26, wherein said EGF-R antagonist is a kinase inhibitor selective for EGF-R.

28. (New) The method of claim 26, wherein the antagonist is administered by injection.

29. (New) The method of claim 28, wherein the antagonist is administered intravenously with a carrier in the form of normal saline solution.

30. (New) The method of claim 26, wherein the antagonist is administered by liposome delivery.

31. (New) The method of claim 30, wherein said liposome is sterically stabilized and administered intravenously.

32. (New) The method of claim 26, wherein the antagonist is administered by inhalation.

33. (New) The method of claim 32, wherein the antagonist is in a dry powder formulation.

34. (New) The method of claim 26, wherein the antagonist is administered by oral delivery.

35. (New) The method of claim 26, wherein the antagonist is in an aqueous or ethanolic solution.

36. (New) The method of claim 26, wherein the patient is a human.